New targets for cancer promotion and therapy in gliomas: Scinderin

doi:10.5306/wjco.v15.i6.687

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3059)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

109

HTML

1273

Sum=1382

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

183

Download

640

Sum=823

Publishing Process of This Article

Item

Count

Browse

159

Download

560

Sum=719

Jun 24, 2024 (publication date) through Feb 15, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Jun 24, 2024; 15(6): 687-690
Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.687

New targets for cancer promotion and therapy in gliomas: Scinderin

Xi Wang, Lian-Xiang Luo

Xi Wang, The First Clinical College, Guangdong Medical University, Zhanjiang 524023, Guangdong Province, China

Lian-Xiang Luo, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China

Author contributions: Luo LX conceived and designed the editorial, contributed to the topic selection, outline formulation, and finalization of the editorial, reviewed the paper and provided comments; Wang X wrote the editorial; and all authors read and approved the final manuscript.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Corresponding author: Lian-Xiang Luo, PhD, Adjunct Associate Professor, The Marine Biomedical Research Institute, Guangdong Medical University, No. 2 Wenming East Road, Zhanjiang 524000, Guangdong Province, China. luolianxiang321@gdmu.edu.cn

Received: January 3, 2024
Revised: April 27, 2024
Accepted: May 20, 2024
Published online: June 24, 2024
Processing time: 173 Days and 7.5 Hours

Abstract

Glioma is one of the most common primary intracranial tumors, characterized by invasive growth and poor prognosis. Actin cytoskeletal rearrangement is an essential event in tumor cell migration. Scinderin (SCIN), an actin severing and capping protein that regulates the actin cytoskeleton, is involved in the proliferation and migration of certain cancer cells. However, its biological role and molecular mechanism in glioma remain unclear. Lin et al explored the role and mechanism of SCIN in gliomas. The results showed that SCIN mechanically affected cytoskeleton remodeling and inhibited the formation of lamellipodia via RhoA/FAK signaling pathway. This study identifies the cancer-promoting role of SCIN and provides a potential therapeutic target for SCIN in glioma treatment.

Keywords: Glioma; Scinderin; Actin cytoskeleton; RhoA/FAK signaling; 1p/19q co-deletion

Core Tip: The role of scinderin (SCIN) in cancer progression has been studied, but its role in glioma remains unknown. Lin et al found that the expression level of SCIN mRNA was positively correlated with the tumor grade of glioma. SCIN affected cytoskeletal remodeling and inhibited lamellipodia formation through RhoA/FAK signaling pathway, thereby facilitating the migration and invasion of glioma cells.